Journal of Pharmacy Technology最新文献

{"title":"Evaluating the Safety of Trough Versus Area Under the Curve (AUC)-Based Dosing Method of Vancomycin With Concomitant Piperacillin-Tazobactam.","authors":"Cassandra Karas, Kyle Manning, Darrell T Childress, Elizabeth W Covington, Melanie M Manis","doi":"10.1177/87551225221101736","DOIUrl":"10.1177/87551225221101736","url":null,"abstract":"<p><p><b>Background:</b> Vancomycin and piperacillin-tazobactam (VPT) is a common antibiotic combination used in hospitals, and there has been increasing data indicating that the combination is associated with increased rates of acute kidney injury (AKI). It is unclear if the dosing method of vancomycin would mitigate the risk of AKI seen with VPT. <b>Objective</b>: To observe and compare incidence of AKI in patients on VPT when using the trough-based dosing method versus the area-under-the-curve (AUC)-based dosing method. <b>Methods</b>: This was a multi-center, retrospective, observational study at 3 community hospitals. Adults receiving at least 48 hours of VPT were included. Patients with severe renal dysfunction, pregnant patients, prisoners, and patients with central nervous system infections, or malignancy were excluded. The primary outcome was incidence of AKI as defined by the Infectious Disease Society of America (IDSA) criteria. <b>Results:</b> A total of 300 patients were included in the study; 150 patients in both the trough and AUC groups. A total of 23 patients (15%) in the trough group and 17 patients (11%) in the AUC group met the primary outcome (odds ratio [OR]: 0.7058, 95% confidence interval [CI]: [0.3603, 1.3826], <i>P</i> = .3098). <b>Conclusion and Relevance</b>: The incidence of AKI was lower in the AUC group compared with the trough group; however, this was not significant. The results of our study suggest that there is no difference between incidence of AKI when using trough- or AUC-based dosing in those receiving VPT. Because of the small sample size and retrospective nature of the study, more data are needed.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272489/pdf/10.1177_87551225221101736.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9622058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Once-Weekly Semaglutide for Weight Management: A Clinical Review.","authors":"Abby Fornes,&nbsp;Jamie Huff,&nbsp;Roger Iain Pritchard,&nbsp;Miranda Godfrey","doi":"10.1177/87551225221092681","DOIUrl":"https://doi.org/10.1177/87551225221092681","url":null,"abstract":"<p><p><b>Objective:</b> To review the efficacy, safety, and role of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide for chronic weight management. <b>Data Sources:</b> A literature search of PubMed/MEDLINE and Google Scholar was performed using the search terms: semaglutide 2.4, weight, and obesity. Ongoing studies of semaglutide were identified utilizing clinicaltrials.gov. <b>Study Selection and Data Extraction:</b> All English-language articles evaluating the efficacy and safety of semaglutide 2.4 mg for weight management in humans were included. <b>Data Synthesis:</b> Once-weekly injectable semaglutide 2.4 mg is indicated as an adjunct to a reduced-calorie diet and increased exercise for chronic weight management in adults with a body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or dyslipidemia. Semaglutide 2.4 mg has consistently demonstrated clinically significant weight loss across all phase 3 STEP (semaglutide treatment effect in people with obesity) trials, and long-term efficacy and safety have been confirmed for up to 2 years. Gastrointestinal side effects were the most frequently reported side effects, including nausea, vomiting, constipation, and diarrhea. Safety data for semaglutide 2.4 mg were consistent with that reported previously for the GLP-1 receptor agonist class. <b>Conclusions:</b> Semaglutide 2.4 mg is a highly efficacious agent for weight management, with a safety profile similar to that of other GLP-1 receptor agonists. It is a feasible option for chronic weight management, with data for up to 2 years. It is currently the only once-weekly weight loss medication, although cost may limit its utilization.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272494/pdf/10.1177_87551225221092681.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9451332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Reappraisal of Oxandrolone in Burn Management.","authors":"Jonathan Kopel, Grant Sorensen, John Griswold","doi":"10.1177/87551225221091115","DOIUrl":"10.1177/87551225221091115","url":null,"abstract":"<p><p><b>Objective:</b> Burn injuries remain among the most severe traumatic injuries globally. With the discovery of cortisol, the use of steroids has become an essential therapy for the management of inflammatory and metabolic conditions. Several studies have shown the steroid oxandrolone improves burn injuries through stimulating anabolic and reducing catabolic processes. In this review, we examine the efficacy and applications of oxandrolone with regard to burn management and treatment. <b>Data Sources:</b> A literature search was performed using the PubMed database from January 1990 to May 2020 to identify articles on oxandrolone and burn management. A total of 18 studies were included in our review. <b>Study Selection and Criteria:</b> The keywords used in our search strategy for PubMed included \"oxandrolone\" and \"burns.\" <b>Data Synthesis:</b> The main benefit of oxandrolone is the improved long-term lean body, protein, and bone mineral mass of burn patients. In addition, 3 separate meta-analyses showed oxandrolone shortened length of hospital stay, donor-site healing time, reduced weight loss, and net protein loss. However, oxandrolone therapy did not affect mortality, infection, or liver function. <b>Conclusion:</b> Oxandrolone remains an effective therapy for reducing the hypermetabolic response and comorbidities from burn injuries. Future clinical trials are needed using larger sample sizes and long-term follow-up to determine whether oxandrolone in the context of rehabilitation programs can reduce mortality, lower treatment costs, and improve function outcomes among burn patients.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272491/pdf/10.1177_87551225221091115.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9457792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationships Between Remote Asynchronous Lectures and Summative Assessment Performance in four Pharmacotherapeutics Courses.","authors":"Jordan Sedlacek,&nbsp;Paul M Boylan,&nbsp;Antonio Perry","doi":"10.1177/87551225221092683","DOIUrl":"https://doi.org/10.1177/87551225221092683","url":null,"abstract":"<p><p><b>Background:</b> Synchronous education describes when teaching, learning, and assessment occur concurrently and asynchronous education describes when teaching, learning, and assessment occur anytime. Remote learning is where teaching and learning occur via technological means. <b>Objective:</b> This report describes a remote, asynchronous learning method implemented in a 3-year, block curriculum, Doctor of Pharmacy degree program. <b>Methods:</b> Remote asynchronous lectures embedded with quizzes were delivered to pharmacy students at the end of their first professional year and beginning of their second professional year. Camtasia software and Screencast.com were utilized during portions of 4 pharmacotherapeutic-based courses. Students completed time-spaced quizzes embedded every 5 to 15 minutes throughout the videos and quiz scores were recorded. Discrete watches, number of total watches, and average number of video quiz questions correctly answered were examined for Spearman's rank correlation coefficient (ρ) with end-of-course summative assessment scores. <b>Results:</b> There were no strong positive correlations between discrete watches, number of total watches, and average number of video quiz questions correctly answered and end-of-course assessment scores (ρ range: -0.47 to 0.25). There were weak to moderate correlations within the rheumatology and dermatology assessment scores based on the Screencast.com content questions and the number of unique video watches (ρ = 0.40), average number of total video watches (ρ = 0.28), and average percent of quiz questions correct (ρ = 0.40), all of which were statistically significant (<i>P</i> < 0.05). <b>Conclusions:</b> Remote asynchronous lectures including time-spaced quizzes were not associated with improvements in summative assessment performance. Mild positive correlations between remote asynchronous lectures and time-spaced quizzes may correspond with discrete questions on a summative assessment but those relationships may be influenced by the content within the remote asynchronous lectures.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272492/pdf/10.1177_87551225221092683.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10014242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiorgan Failure After Phentermine Overdose.","authors":"Gia Thinh D Truong,&nbsp;Zachary A Creech,&nbsp;Shraddha Narechania,&nbsp;Mark A Malesker","doi":"10.1177/87551225221088980","DOIUrl":"https://doi.org/10.1177/87551225221088980","url":null,"abstract":"Phentermine is the most prescribed anorexiant in the United States. There is a paucity of literature on consequences of phentermine overdose.1 We present a case of multiorgan failure secondary to phentermine self-overdose in an elderly male. A 69-year-old man with a history of epilepsy, major depressive disorder, prior methamphetamine abuse, schizophrenia, suicidal ideation, and cerebrovascular accident presented to the emergency department following intentional overdose of approximately 750 mg of phentermine. His home medications included quetiapine, aspirin, lisinopril, and phentermine. Urine drug analysis was positive for amphetamines, tricyclics, and bupropion. Acetaminophen, salicylate, and alcohol were not detected in the toxicology screen. A phentermine blood level was not ordered. Upon presentation, the patient was alert and able to follow commands while endorsing excessive muscle twitching and spastic movements. Vital signs upon presentation revealed a temperature of 36.7°C, heart rate of 135 beats/minute, respiratory rate of 24 breaths/minute, blood pressure of 185/125 mm Hg, and oxygen saturation of 94% on room air. He was tachycardic, tachypneic, and hypertensive. An electrocardiogram demonstrated atrial fibrillation followed by regular, narrow complex supraventricular tachycardia with a right bundle branch block. Atelectasis was seen in the left lung base. Initial labs were significant for leukocytosis, acute kidney injury, rhabdomyolysis, metabolic acidosis, and transaminitis. Computed tomography of the head and chest was unremarkable. An echocardiogram revealed an ejection fraction of 10% to 15%, akinetic apex, and multiple areas of hypokinesis consistent with stress cardiomyopathy. He subsequently became more agitated requiring intubation and ICU admission. Emergent hemodialysis was required given worsening acidosis, kidney injury, hyperkalemia, and rhabdomyolysis. The patient also received brief use of vasopressors. The creatine kinase peaked at 14 000 U/L, and troponin concentration peaked at 38 ng/mL before trending down. The patient’s acute renal failure and anion gap metabolic acidosis were corrected after 2 rounds of dialysis. He was extubated after 5 days of ventilation. On day 11, the patient was discharged to a skilled nursing facility. Phentermine is a centrally acting sympathomimetic amine that suppresses appetite and assists with short-term weight loss.1 Phentermine has a high potential of misuse. Adverse effects of tachycardia, decreased visual acuity, nausea, sleeplessness, anxiety, psychosis, and manic-like episodes are linked with phentermine therapy.2 Cardiac complications can arise due to enhanced AV nodal conduction effects from a similar structure to amphetamine.3 Case reports have described the development of prolonged QT interval and polymorphic ventricular tachycardia, supraventricular tachycardia, and recurrent ventricular fibrillation with cardiac vasospasm.3 One case report described the onset of rhabdomy","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116121/pdf/10.1177_87551225221088980.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9418434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prescribing Patterns of Antihypertensive Agents and Blood Pressure Control Among Patients With Incident Stage 2 Hypertension.","authors":"Micah V Helms,&nbsp;Ashley L Edwards,&nbsp;Taylor H Suszynsky,&nbsp;Andrew Y Hwang","doi":"10.1177/87551225211069802","DOIUrl":"https://doi.org/10.1177/87551225211069802","url":null,"abstract":"<p><p><b>Background:</b> Initiation of appropriate antihypertensive therapy is crucial, particularly among patients with stage 2 hypertension, whom initiation of dual antihypertensive agents is suggested. Little is known regarding real-world prescribing of antihypertensive agents for patients with incident stage 2 hypertension. <b>Objective:</b> The primary objective was to describe prescribing patterns of antihypertensive therapy among patients with incident stage 2 hypertension. The secondary objectives included determining association of blood pressure (BP) control with initial multiple antihypertensive agents. <b>Methods:</b> Retrospective cohort analysis was conducted using electronic medical records from 6 primary care clinics between January 2014 and June 2019. Included patients were ≥18 years with an initial diagnosis of stage 2 hypertension, defined as BP ≥160/100 mm Hg Primary analysis was characterizing prescribing patterns of antihypertensive agents among patients with incident stage 2 hypertension. Investigation of BP control (<140/90 mm Hg) at 3 months of diagnosis was also performed. <b>Results:</b> We identified 261 patients with incident stage 2 hypertension (mean age, 52 years; 53.2% males; mean baseline BP, 162.1/100.1 mm Hg). Approximately 72% of patients were initiated on single antihypertensive agent, with the most common being angiotensin receptor blockers (ARBs; 25.7%) and angiotensin-converting-enzyme (ACE) inhibitors (24.6%). Commonly initiated multiple antihypertensive agents were ACE-inhibitor + thiazide-like diuretic (52.7%), followed by an ARB + thiazide-like diuretic (21.6%). Multiple antihypertensive therapy was associated with improved BP control at 3 months (adjusted odds ratio [OR], 3.54; 95% confidence interval [CI], 1.55-8.06). <b>Conclusion:</b> Majority of patients with incident stage 2 hypertension were prescribed initial single antihypertensive therapy, though better BP control at 3 months was seen among those initiated on multi-antihypertensive therapy.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116125/pdf/10.1177_87551225211069802.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10624644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential Drug Interactions Between Psychotropics and Intravenous Chemotherapeutics Used by Patients With Cancer.","authors":"Eric Diego Turossi-Amorim,&nbsp;Bruna Camargo,&nbsp;Diego Zapelini do Nascimento,&nbsp;Fabiana Schuelter-Trevisol","doi":"10.1177/87551225211073942","DOIUrl":"https://doi.org/10.1177/87551225211073942","url":null,"abstract":"<p><p><b>Introduction:</b> Patients undergoing cancer treatment usually have comorbidities, and psychiatric disorders are commonly seen in these patients. For the treatment of these psychiatric disorders, the use of psychotropic drugs is common, turning these patients susceptible to untoward drug interactions. Therefore, the aim of this study was to estimate the prevalence of clinically relevant drug-drug interactions (DDI) between chemotherapeutic and psychotropic agents in patients with cancer treated at an oncology service in southern Brazil. <b>Methods:</b> An observational epidemiological study with a cross-sectional census-type design was carried out between October and December 2020. The drug-drug interactions were identified through consultation and analysis of the Medscape Drug Interaction Check and Micromedex databases. The interactions were classified as major, when the interaction can be fatal and/or require medical intervention to avoid or minimize serious adverse effects and moderate, when the interaction can exacerbate the patient's condition and/or requires changes in therapy. <b>Results:</b> A total of 74 patients was included in the study among the 194 patients seen in the oncology service during the period studied. A total of 24 (32.4%) DDIs were found, 21 (87.5%) of which were classified as being of major risk and 3 (12.5%) as moderate risk. According to the mechanism of action, 19 (79.1%) were classified as pharmacodynamic interactions and 5 (20.9%) as pharmacokinetic interactions. <b>Conclusion:</b> It was shown that a considerable percentage of patients undergoing intravenous chemotherapy are at risk of pharmacological interaction with psychotropic drugs. Thus, it is essential that the oncologist considers all psychotropic drugs and other drugs used by patients in order to avoid drug-drug interactions.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116124/pdf/10.1177_87551225211073942.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10799021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Monoclonal Antibodies in Preventing Hospitalizations, Emergency Department Visits, and Mortality in High-Risk COVID-19 Patients.","authors":"Ashlee N Milam,&nbsp;Diana T Doan,&nbsp;Darrell T Childress,&nbsp;Spencer H Durham","doi":"10.1177/87551225221080027","DOIUrl":"https://doi.org/10.1177/87551225221080027","url":null,"abstract":"<p><strong>Background: </strong>The coronavirus disease 2019 (COVID-19) is a novel coronavirus that has caused an unprecedented global pandemic, with few treatment options currently available. Neutralizing monoclonal antibodies (mAbs) are a promising treatment approach to reduce hospitalizations in high-risk patients with mild-to-moderate COVID-19 infections.</p><p><strong>Objective: </strong>The primary objective is to compare hospitalization rates of high-risk patients who tested positive for COVID-19 within 28 days between those who received mAb infusions versus those who did not. Secondary objectives were emergency department (ED) visits and mortality within 28 days of a positive test.</p><p><strong>Methods: </strong>This single-center, institutional review board-approved, retrospective, observational cohort study included patients aged 19 years and older who tested positive for COVID-19 between December 2, 2020 and February 28, 2021. Patients who received the mAbs bamlanivimab or casirivimab/imdevimab were compared with patients who did not receive mAb infusions to examine hospitalization rates, ED visits, and mortality within 28 days of the positive COVID-19 test.</p><p><strong>Results: </strong>A total of 2780 patients were evaluated for inclusion using electronic chart review via Cerner. Of the 1612 patients who met inclusion criteria, 568 received an mAb infusion (mAb group) and 1044 did not (non-mAb group). Baseline characteristics were similar between the 2 groups. Of the patients in the mAb group, 34 (6%) were hospitalized versus 397 (38%) in the non-mAb group. Patients with ED visits included 111 (20%) and 672 (64%) in the mAb and non-mAb groups, respectively. Finally, 5 patients in the mAb group experienced mortality (0.9%) versus 83 (8%) in the non-mAb group. Each endpoint achieved statistical significance with a <i>P</i> value of <0.0001.</p><p><strong>Conclusion: </strong>Monoclonal antibody infusions are effective in preventing hospitalization, ED visits, and mortality in high-risk patients with mild-to-moderate COVID-19.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116122/pdf/10.1177_87551225221080027.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10252886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Current Hazardous Drug Exposure Control in Community Pharmacy.","authors":"John Papastergiou,&nbsp;Tom Smiley","doi":"10.1177/87551225211072743","DOIUrl":"https://doi.org/10.1177/87551225211072743","url":null,"abstract":"<p><p><b>Purpose</b>: To evaluate effectiveness of current hazardous drug exposure control practices in community pharmacies through identification of commonly contaminated surfaces. We also assessed the decontamination effectiveness of 5 different cleaning agents. <b>Methods</b>: This study was prospective and nonrandomized and conducted in 2 phases. In phase 1, 15 common areas used in the dispensing process were tested at each of 4 pharmacies in Toronto Ontario, Canada. Testing was conducted using the BD^® HD Check System, a rapid, point-of-care, hazardous drug detection system that is able to identify contamination with methotrexate (MTX) and cyclophosphamide (CYP) and doxorubicin. In phase 2, 5 different cleaning agents (70% isopropyl alcohol, Lysol^® spray, Ecolab^® retail multiquat sanitizer, Ecolab retail multisurface and glass cleaner with peroxide, and Ecolab QSR heavy-duty degreaser) were tested for their ability to eliminate contamination. <b>Results</b>: All 4 pharmacies tested positive for contamination with MTX (25.8% of surfaces). Contamination with CYP was less frequent, with only 3 sites and 18.2% of surfaces testing positive. Of the 5 cleaning agents tested, only Ecolab QSR heavy-duty degreaser was able to eliminate contamination with MTX. None of the agents were successful against CYP. <b>Conclusions:</b> The results illustrate an unacceptable prevalence of hazardous drug contamination in community pharmacy settings. The BD HD Check System can serve to rapidly detect common high-risk areas for surface contamination. Decontamination protocols against MTX may include Ecolab QSR heavy-duty degreaser. Novel agents must be identified to remove contamination caused by CYP.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116126/pdf/10.1177_87551225211072743.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10252891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of Community Pharmacy Competencies.","authors":"Pantira Parinyarux,&nbsp;Teerapon Dhippayom,&nbsp;Payom Wongpoowarak,&nbsp;Nantawarn Kitikannakorn","doi":"10.1177/87551225221081370","DOIUrl":"https://doi.org/10.1177/87551225221081370","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to develop a consensus statement of competencies for community pharmacists in Thailand.</p><p><strong>Methods: </strong>A 2-round modified Delphi process was used to develop consensus among a panel of community pharmacy experts. A total of 18 experts from 6 stakeholders represented a panel of each pharmacy organization in Thailand. In the first experts were asked to rate their degree of agreement on whether a competency was essential using a 7-point Likert scale (1 = \"not essential competency\" to 7 = \"the most essential competency\"). Also, in the second round, they were asked to rate the competencies from a scale of \"must be included\" to \"must be excluded.\" Competencies considered \"must be excluded\" by a consensus of 80% or more of experts were removed from the community pharmacy competency list.</p><p><strong>Results: </strong>Nearly half the experts had experience in their position for more than 10 years. The expert panels were typically committee members of the Community Pharmacy Association (Thailand) and community pharmacy clerkship preceptors (29.4% and 23.5%, respectively). The number of community pharmacy competencies on the initial list was 55 competencies. None of them was eliminated after the first round. Of 55 competencies, 11 were eliminated after the second round. The final list of competency statements was 44 competencies divided into 4 domains: personal competencies, pharmacy professional competencies, patient care competencies, and management competencies.</p><p><strong>Conclusion: </strong>Community pharmacy competencies include having a positive attitude and being accountable for individual patient care, providing disease prevention and health promotion, and addressing morality and ethics in business.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116120/pdf/10.1177_87551225221081370.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10252893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}